Last updated on February 2018

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Brief description of study

In this phase I pilot study, it is planned to investigate the feasibility and safety of adding an interferon therapy to an preexisting imatinib treatment in patients with chronic phase chronic myeloid leukaemia. The participating patients have already reached a response during their imatinib therapy (CCyR) but have still a detectable disease (no molecular response MR 4.5 or better).

Clinical Study Identifier: NCT01933906

Contact Investigators or Research Sites near you

Start Over

Sonja Burgstaller, MD

Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung
Wels, Austria
  Connect »

Micheal Steurer, Prof.MD

Universit tskliniken Innsbruck, Univ.-Klinik f.Innere Medizin V H mtologie u. Onkologie
Innsbruck, Austria
  Connect »

Veronika Buxhofer-Ausch, MD

Ordensklinikum Linz - Elisabethinen
Linz, Austria
  Connect »

Richard Greil, MD

Universit tsklinikum der PMU Salzburg, Universit tsklinik f r Innere Medizin III
Salzburg, Austria
  Connect »

Wolfgang Füreder, MD, Prof.

Med. Univ. Wien, Univ.Klinik f. Innere Medizin I, Hematologie/Hemostaseologie
Vienna, Austria
  Connect »

Thamer Sliwa, MD

Hanusch-Krankenhaus, 3. Medizinische Abteilung
Vienna, Austria
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.